Last reviewed · How we verify
Poly-gamma Glutamic Acid
At a glance
| Generic name | Poly-gamma Glutamic Acid |
|---|---|
| Sponsor | BioLeaders Corporation |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma (EARLY_PHASE1)
- Efficacy and Safety Study of PGA (Poly-gamma Glutamic Acid) for Cervical Intraepithelial Neoplasia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Poly-gamma Glutamic Acid CI brief — competitive landscape report
- Poly-gamma Glutamic Acid updates RSS · CI watch RSS
- BioLeaders Corporation portfolio CI